nVision Medical Company

Acquired by Boston Scientific. nVision developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Recent studies have confirmed that several major types of ovarian cancer appear to originate from the fallopian tubes.
Industry: General Health Care
Headquarters: San Bruno, California, United States
Founded Date: 2009-01-01
Funding Status: M&A
Total Funding: $16 405 000
Estimated Revenue: $1M to $10M
Last Funding Date: 2016-07-21
Last Funding Type: Series B

Visit Website
Register and Claim Ownership